Q2 2025 Scientific Industries Inc Earnings Call Transcript
Key Points
- Scientific Industries Inc (SCND) successfully sold its legacy Genie products division to Mettler-Toledo, marking a strategic shift towards AI-powered life science platforms.
- The company is focusing on innovative technologies such as computer vision-based automated pill counters and bioprocessing solutions, positioning itself as a pioneer in these fields.
- The Torbal division continues to provide solid and predictable cash flows with opportunities for growth.
- Significant progress was made in R&D, including advancements in dissolved oxygen sensing, biomass monitoring, and glucose sensing technologies.
- Engagement with leading biopharma companies like Genentech, Amgen, Biogen, and Johnson & Johnson has deepened, indicating potential for future commercial agreements.
- The broader laboratory tools and bioprocessing sector is facing a subdued operating environment with softer order volumes and extended procurement cycles.
- Revenue softness remains a short-term reality due to macroeconomic factors, including tight research budgets and uncertainty in biotech funding.
- Academic sales have significantly decreased, representing only 6% of total revenue year-to-date compared to 24% in 2024.
- The market environment has led to longer purchasing cycles and greater selectivity in capital projects, impacting revenue.
- Scientific conferences, a key engagement channel, are experiencing lower attendance due to tighter travel and event budgets, reducing immediate conversion opportunities.
Good day, and welcome to the Scientific Industries second-quarter fiscal year 2025 financial results conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Joe Dorame, Managing Partner. Please go ahead.
Thanks, Michael. Good morning and thank you all for joining us today to review Scientific Industries financial results for the second-quarter of 2025 ended June 30, 2025. With us today on the call are Helena Santos, Chief Executive Officer; Daniel Donadille, CEO of SBI; and John Moore, Chairman. After the conclusion of today's prepared remarks, we will open the call for questions.
Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of scientific industries during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Except for the statements of historical fact,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
